CASI Pharmaceuticals logo
CASI Pharmaceuticals CASI

Quarterly report 2022-Q3
added 11-14-2022

report update icon

CASI Pharmaceuticals Financial Statements 2011-2026 | CASI

Annual Financial Statements CASI Pharmaceuticals

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.09 B 371 M 285 M 300 M 255 M 74.3 M 35 M 45.5 M 49.9 M 39.6 M 28.2 M

Shares

136 M 110 M 95.9 M 84.8 M 61.5 M 55.9 M 32.4 M 28.6 M 26.1 M 19.1 M 11.8 M

Historical Prices

8.4 24.6 17.7 32.8 34.6 14.2 7.9 16.2 18.9 29.5 20.7

Net Income

-36.7 M -48.3 M -46 M -27.5 M -10.8 M -9.45 M -7.21 M -26.2 M -5.74 M -14.5 M -4.56 M

Revenue

30.2 M 15.1 M 4.13 M - - - 47.7 K 23.7 K - 669 K 1.94 M

Cost of Revenue

12.6 M 9.51 M 3.94 M - - - - - - - -

Gross Profit

17.6 M 5.63 M 196 K - - - 41.4 K 16.3 K - 669 K 1.94 M

Operating Income

-41.8 M -51.5 M -47 M -27.2 M - - - - - - -

Interest Expense

2.9 K 3.1 K 5.6 K 7.5 K 7.5 K -26.1 K -81.5 K -26.6 K 1.66 K 10 M -

EBITDA

-41.4 M -30.1 M -37.8 M -24.8 M -10.6 M -9.35 M -7.08 M -6.46 M -5.72 M -4.48 M -4.53 M

Operating Expenses

- 38.9 M 40.2 M 26.5 M 10.8 M 9.42 M 7.19 M 6.52 M 5.74 M 5.17 M 6.51 M

General and Administrative Expenses

23.8 M 19.7 M 27.3 M 18 M 3.16 M 4.78 M 3.12 M 3.76 M 2.99 M 2.8 M 3.05 M

All numbers in USD currency

Quarterly Income Statement CASI Pharmaceuticals

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 13.6 M 13.6 M 138 M 14 M 14 M 14 M 125 M 124 M 118 M 101 K 98.8 K 97.8 M 95.9 K 95.7 K 95.6 K 95.3 M 81.5 K 86 M 71.2 M 69.8 M 60.2 M 60.2 M 60.2 M - 49.2 M 42.9 M 40.2 M - 32.4 M 32.4 M 32.4 M - 27.8 M 27 M 27 M 27.1 M 27 M 27 M 23.4 M 22.6 M 22.5 M 19 M 12.2 M 12.2 M 12 M 11.5 M 12.2 M

Net Income

- -5.2 M -7.68 M -8.6 M - -10.2 M -6.95 M -13.9 M - -17 M -8.69 M -8.44 M - -9.89 M -15.5 M -8.18 M - -8.76 M -5.86 M -3.59 M - -1.61 M -2.41 M -1.7 M - -1.69 M -3.29 M -1.79 M - -1.6 M -2.1 M -1.8 M - -21.5 M -1.62 M -1.45 M - -1.44 M -1.85 M -1.14 M - -1.19 M -10.5 M -2.53 M - -1.31 M -1.66 M -2.6 M

Revenue

- 10.2 M 8.57 M 9.06 M - 8.11 M 7.16 M 5.74 M - 4.24 M 2.67 M 3.41 M - 2.79 M - - - - - - - - - - - - - - - - 24 K 23.7 K - - - - - - - - - - - - - - 8.85 K -

Cost of Revenue

- 4.25 M 3.55 M 3.76 M - 3.42 M 2.98 M 2.36 M - 1.83 M 2.52 M 3.21 M - 2.65 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 5.97 M 5.02 M 5.3 M - 4.7 M 4.18 M 3.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -6.35 M -7.75 M -7.29 M - -6.89 M -7.98 M -15.6 M - -18.7 M -8.89 M -8.77 M - -10.6 M -15.8 M -8.32 M - -8.71 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 11 K 11 K 38 K - 487 K 33 K 1 M - 1.2 K 700 190 K - 414 K 320 K 49 K - 11 K 13.1 K 6.73 K - -546 -72 142 - -5.61 K -8.76 K -8.77 K - -24.3 K -24.3 K -24.2 K - -2.93 K 129 384 - 408 443 -390 - - 9.17 M 876 K - - - -

EBITDA

- -5.79 M -7.64 M -7.2 M - -6.5 M -7.67 M -15.4 M - -18.3 M -8.61 M -8.62 M - -10.1 M -15.2 M -8.19 M - -8.46 M 142 K 65.8 K - 69.4 K 37.9 K 18.5 K - 48 K 32.5 K 19 K - 50.8 K 33.2 K 16.5 K - 32.7 K 19.2 K 6.53 K - 12.9 K 9.04 K 4.66 K - 15.1 K 9.38 K 4.23 K - 33.6 K 23.7 K 12.1 K

General and Administrative Expenses

- 4.85 M 5.52 M 5.32 M - 5.26 M 5.49 M 5.5 M - 5.35 M 4.08 M 4.06 M - 7.98 M 6.98 M 5.71 M - 6.9 M 4.04 M 1.3 M - 626 K 691 K 644 K - 677 K 1.91 M 765 K - 674 K 858 K 925 K - 1.15 M 892 K 891 K - 663 K 1.02 M 630 K - 565 K 602 K 1.1 M - 557 K 720 K 1.25 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements CASI Pharmaceuticals CASI
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting CASI Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.34 3.6 % $ 43.3 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.25 1.81 % $ 908 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 2.96 -1.0 % $ 252 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.28 0.11 % $ 27.2 B germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.09 -0.97 % $ 437 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.22 2.37 % $ 225 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.37 1.0 % $ 2.08 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.66 0.11 % $ 3.01 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Ardelyx Ardelyx
ARDX
$ 5.97 0.51 % $ 1.44 B usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
argenx SE argenx SE
ARGX
$ 748.25 0.25 % $ 25 B niderlandNiderland